Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFRT vs PULSAR with CAPOX and PD-1 in Gastric/GEJ Cancer
NCT06728657Phase 2Suspended
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction cancer (2 arms), sponsored by Fudan University. Primary endpoint: Pathological Complete Regression Rate at 6 months. Started Jul 2024; status: suspended.
02
Conditions
gastric adenocarcinomagastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06728657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728657.